| Source: |
Escherichia coli |
| Molecular Weight: |
Approximately 7.7 kDa, a single polypeptide chain containing 70 amino acids. |
| AA Sequence: |
GPETLCGAEL VDALQFVCGD RGFYFNKPTG YGSSSQRAPQ TGIVDECCFR SCDLRRLEMY CAPLKPAKSA |
| Purity: |
> 95% by SDS-PAGE analyses. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 µm filtered concentrated solution in 20 mM PB, 150 mM NaCl, pH5.4. |
| Endotoxin: |
Less than 0.1 EU/µg of rHuIGF-1 R36Q as determined by LAL method. |
| Reconstitution: |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Background: |
IGF-1, a member of the insulin gene family, is a mitogenic polypeptide growth factor that promotes the proliferation and survival of diverse cell types such as muscle, bone, and cartilage tissue in vitro. It is primarily synthesized by the liver as an endocrine hormone and also locally in target tissues in a paracrine or autocrine manner. Production of IGF-1 is stimulated by growth hormone (GH) and can be inhibited by conditions such as undernutrition, growth hormone insensitivity, absence of growth hormone receptors, or disruptions in downstream signaling pathways post GH receptor activation, involving proteins like SHP2 and STAT5B. |
